Rheumatoid Arthritis Treatment Market Analysis

Product Type Segment Analysis 

Based on the product type, the biologics segment is predicted to capture the largest share at 63% in the rheumatoid arthritis treatment market over the assessed period. Biologics, including both the originators and the biosimilars, will continue to dominate because they continue to show a great deal of efficacy, especially in cases of severe RA. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) standards highlight the rationale for using biosimilars that have an approximate 58% cost savings each time a biosimilar is used. Biologics gain more covered decisions in the clinical guidelines, and will retain the highest market share.

Drug Category Segment Analysis  

In terms of drug category, the biosimilars segment is anticipated to hold the highest revenue proportion of 36% in the rheumatoid arthritis treatment market throughout the discussion. Globally, payer cost containment strategies drive biosimilar uptake. CDC states biosimilars substantially reduce immunogenicity risks and cost burdens. The biosimilar introductions into the EU and US markets enabled innovative payers to begin shifting biosimilars into their reimbursement formularies. This made biosimilars one of the hick rapid growing sub segments of pharmaceuticals.

Our in-depth analysis of the global market includes the following segments: